NanoRepro AG (NN6) - Total Liabilities

Latest as of June 2025: €694.21K EUR ≈ $811.60K USD

Based on the latest financial reports, NanoRepro AG (NN6) has total liabilities worth €694.21K EUR (≈ $811.60K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of NanoRepro AG to assess how effectively this company generates cash.

NanoRepro AG - Total Liabilities Trend (2008–2024)

This chart illustrates how NanoRepro AG's total liabilities have evolved over time, based on quarterly financial data. Check NN6 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

NanoRepro AG Competitors by Total Liabilities

The table below lists competitors of NanoRepro AG ranked by their total liabilities.

Company Country Total Liabilities
Higher Way Electronic Co Ltd
TWO:3268
Taiwan NT$548.21 Million
Tuju Setia Bhd
KLSE:5297
Malaysia RM447.21 Million
Smithson Investment Trust PLC
LSE:SSON
UK GBX1.63 Million
Indivior PLC
LSE:INDV
UK GBX1.71 Billion
Naos Ex-50 Opportunities Company Ltd
AU:NAC
Australia AU$18.30 Million
Overactive Media Corp
V:OAM
Canada CA$21.11 Million
Century Extrusions Limited
NSE:CENTEXT
India Rs933.40 Million
Greggs PLC
LSE:GRG
UK GBX773.20 Million

Liability Composition Analysis (2008–2024)

This chart breaks down NanoRepro AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NN6 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 32.12 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 23.20 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.02 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.02 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NanoRepro AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NanoRepro AG (2008–2024)

The table below shows the annual total liabilities of NanoRepro AG from 2008 to 2024.

Year Total Liabilities Change
2024-12-31 €884.03K
≈ $1.03 Million
-18.30%
2023-12-31 €1.08 Million
≈ $1.27 Million
-47.01%
2022-12-31 €2.04 Million
≈ $2.39 Million
-90.52%
2021-12-31 €21.54 Million
≈ $25.18 Million
+577.36%
2020-12-31 €3.18 Million
≈ $3.72 Million
+749.78%
2019-12-31 €374.21K
≈ $437.49K
+98.93%
2018-12-31 €188.12K
≈ $219.93K
-49.61%
2017-12-31 €373.31K
≈ $436.44K
-22.03%
2016-12-31 €478.78K
≈ $559.74K
+190.84%
2015-12-31 €164.62K
≈ $192.46K
-37.88%
2014-12-31 €265.00K
≈ $309.81K
+88.29%
2013-12-31 €140.74K
≈ $164.54K
-29.07%
2012-12-31 €198.42K
≈ $231.97K
+41.75%
2011-12-31 €139.97K
≈ $163.65K
-62.53%
2010-12-31 €373.59K
≈ $436.76K
+51.56%
2009-12-31 €246.49K
≈ $288.18K
+25.89%
2008-12-31 €195.80K
≈ $228.91K
--

About NanoRepro AG

XETRA:NN6 Germany Diagnostics & Research
Market Cap
$22.34 Million
€19.11 Million EUR
Market Cap Rank
#25229 Global
#2180 in Germany
Share Price
€1.52
Change (1 day)
-0.98%
52-Week Range
€1.22 - €1.98
All Time High
€17.14
About

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more